Albumin in Urine in Multiple Myeloma
Patients with multiple myeloma typically do NOT have albumin as their primary urinary protein—instead, they excrete monoclonal light chains (Bence Jones protein), though albumin can be present as a secondary finding in some cases, particularly when there is glomerular damage.
Primary Urinary Protein in Multiple Myeloma
- The characteristic urinary finding in multiple myeloma is monoclonal light chain proteinuria (Bence Jones protein), not albumin 1
- Routine urinalysis and 24-hour urine collection for protein electrophoresis and immunofixation are essential diagnostic tests to identify and quantify monoclonal proteins in urine 1
- Approximately 20% of multiple myeloma patients have measurable urinary monoclonal proteins (Bence Jones proteinuria) 1
- The presence of Bence Jones proteinuria is significantly associated with renal failure in myeloma patients 2
When Albumin May Be Present
Albuminuria can occur in multiple myeloma patients as a secondary phenomenon, particularly when there is:
- Glomerular damage or nephrotic syndrome, which should raise suspicion for AL amyloidosis or light chain deposition disease 2
- Renal impairment with glomerular involvement—urinary albumin excretion >25% is associated with poorer renal recovery and suggests glomerular disease that is difficult to reverse 3
- Advanced renal dysfunction—albumin may be detected alongside other markers of tubular and glomerular damage 4
Clinical Significance of Urinary Proteins
- Urinary albumin, IgG, and α1-microglobulin are more sensitive than serum creatinine or urea for detecting early renal damage in myeloma patients 4
- When both Bence Jones proteinuria and nephrotic-range albuminuria coexist, this strongly suggests AL amyloidosis or light chain deposition disease rather than simple cast nephropathy 2
- In light chain deposition disease specifically, Bence Jones proteinuria may be absent in 30% of cases, but albumin may still be present 2
Diagnostic Workup for Proteinuria
The standard evaluation includes:
- 24-hour urine collection for total protein quantification, electrophoresis, and immunofixation to identify monoclonal light chains 1, 5
- Serum free light chain assay to determine kappa/lambda ratio and quantify involved light chains 1, 5
- Urinary albumin measurement can be added to assess for glomerular involvement, particularly in patients with renal impairment 4, 3
Prognostic Implications
- Initial 24-hour daily protein excretion ≥500 mg/day before treatment is associated with significantly worse survival (17.51 vs 34.24 months, p=0.002) 6
- Urinary albumin excretion >25% predicts poor renal recovery in myeloma patients with moderate to severe renal impairment 3
- Serum albumin <2.8 g/dL is an independent risk factor for mortality (hazard ratio 0.486, p=0.029) 6
Key Clinical Pitfall
Do not confuse the presence of albumin in urine with the diagnostic monoclonal light chain proteinuria of multiple myeloma—albumin is not the primary pathologic protein but may indicate additional glomerular pathology requiring further investigation for amyloidosis or light chain deposition disease 2.